Open AccessDocetaxel Rechallenge in a Heavily Pretreated Patient With Castration-Resistant Prostate Cancer
Author(s) -
Giuseppe Di Lorenzo,
Martina Pagliuca,
Teresa Perillo,
Alfonso Benincasa,
Davide Bosso,
Sabino De Placido,
Carlo Buonerba
Publication year - 2016
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000002754
Subject(s) - docetaxel , cabazitaxel , medicine , prostate cancer , enzalutamide , oncology , chemotherapy , adverse effect , taxane , toxicity , cancer , androgen deprivation therapy , androgen receptor , breast cancer
Chemotherapy agents for patients with metastatic castration-resistant prostate cancer (mCRPC) include docetaxel and cabazitaxel. Although docetaxel is approved in the first-line treatment setting, a few studies have shown that selected patients can benefit from docetaxel rechallenge. We, here, report the case of a heavily pretreated mCRPC patient who reported clinical benefit from receiving docetaxel after previous exposure to docetaxel, cabazitaxel, abiraterone, and enzalutamide. After 4 cycles of treatment, patient's performance status had improved to 1, the hemoglobin level was 12.9 g/dL and his serum prostate specific antigen levels were reduced by >70%, with no treatment-related adverse events. Although docetaxel rechallenge is a therapeutic option for selected patients, the risk of cumulative toxicity described in literature must be carefully considered. As the risk of cabazitaxel-related cumulative toxicity is probably lower, retreatment with cabazitaxel rather than docetaxel may also be an option in the setting of heavily pretreated mCRPC patients.